Cyclic Citrullinated Peptide (CCP): What It Is and Why It's Tested

Key Takeaways

• What it measures: Anti-CCP detects IgG-class antibodies targeting citrullinated proteins — the defining autoantibody of seropositive rheumatoid arthritis.
• Typical reference range: Negative: below 20 U/mL (most CCP2-generation assays); weakly positive: 20–39 U/mL; moderately positive: 40–59 U/mL; strongly positive: 60 U/mL or above. Thresholds vary by laboratory and assay generation.
• Sample type: Serum (standard red-top or serum separator tube).
• Fasting required: No.
• When providers order it: Suspected rheumatoid arthritis, undifferentiated inflammatory arthritis, family history of RA, pre-clinical RA screening in at-risk individuals.
• Test frequency: Typically ordered once at initial evaluation; serial measurement is not generally required for diagnosis.
• Key confounder: Tuberculosis and occasionally other infections can produce a weakly positive anti-CCP result; the clinical picture must accompany interpretation.

What Cyclic Citrullinated Peptide Is and What the Test Measures

The anti-CCP (anti-cyclic citrullinated peptide) test detects IgG-class autoantibodies that the immune system produces against proteins containing citrulline, a modified amino acid created when the enzyme PAD (peptidylarginine deiminase) converts arginine residues within proteins into citrulline. This conversion — called citrullination — is a routine post-translational modification in normal cell biology, occurring in neutrophil extracellular traps, dying cells undergoing apoptosis, and inflamed tissue. In rheumatoid arthritis, this ordinary process becomes a trigger for autoimmunity: the body generates antibodies against its own citrullinated proteins at levels detectable in blood, often years before joint damage is clinically apparent. These antibodies are collectively referred to as anti-citrullinated protein antibodies (ACPA), and the anti-CCP assay is the standardized commercial test used to detect them. Schellekens and colleagues, publishing in Arthritis and Rheumatism in 2000, established the diagnostic properties of the cyclic citrullinated peptide assay — the foundational paper that introduced the modern CCP test to clinical practice. The "cyclic" in the name refers to a structural feature of the synthetic antigen used in the assay: peptide chains are chemically cyclized to better mimic the conformation of naturally citrullinated proteins, which substantially improves detection accuracy compared to earlier linear-peptide assays.

Anti-CCP Reference Ranges

Most commercial anti-CCP assays use the CCP2 or CCP3 antigen generation. Results are typically reported in units per milliliter (U/mL), though some labs use arbitrary units. The tiers below reflect common CCP2 assay conventions; values vary by laboratory and assay platform.

• Negative: Below 20 U/mL
• Weakly positive: 20–39 U/mL
• Moderately positive: 40–59 U/mL
• Strongly positive: 60 U/mL or above
• High-positive (ACR/EULAR criterion): Greater than 3 times the upper limit of normal (typically above 60 U/mL on standard assays)

Reference ranges vary by laboratory and individual. The values above represent typical population-derived reference intervals for second-generation CCP assays and are not diagnostic thresholds. Your provider will interpret your specific result alongside symptoms, medical history, and other test findings.

What Citrullination Is and Why It Matters in RA

The biochemistry of citrullination

Citrullination is catalyzed by a family of calcium-dependent enzymes called peptidylarginine deiminases (PADs). Vossenaar and colleagues, in a 2003 review published in BioEssays, characterized the PAD gene family including PAD1, PAD2, PAD3, PAD4, and PAD6 — distinct enzymes expressed in different tissues. PAD4, encoded by the PADI4 gene, is expressed primarily in immune cells including neutrophils and macrophages. Curran and colleagues, in a 2020 review in Nature Reviews Rheumatology, comprehensively characterized PAD enzyme activity in RA, documenting how the citrullinating enzymes are activated at sites of inflammation and how this generates the antigenic substrates that drive the anti-CCP immune response. In RA-susceptible individuals, the immune system may fail to maintain tolerance to citrullinated self-proteins — a breakdown in normal immunological checkpoints that allows anti-CCP antibodies to accumulate.

Why certain people develop anti-CCP antibodies

Not everyone exposed to citrullinated proteins generates autoantibodies against them. The development of anti-CCP positivity appears to require a convergence of genetic predisposition and environmental triggers. The strongest genetic signal comes from the HLA-DRB1 shared epitope — a cluster of amino acid sequences in specific HLA class II alleles that are disproportionately represented in anti-CCP-positive RA patients. Suzuki and colleagues, in a 2003 paper in Nature Genetics, demonstrated that functional haplotypes of PADI4 are associated with RA susceptibility in Japanese and UK cohorts, providing a direct genetic link between the citrullinating enzyme and RA risk. Klareskog and colleagues, in a 2006 paper in Arthritis and Rheumatism, proposed that smoking activates PAD enzymes in lung tissue, generating citrullinated peptides that trigger an HLA-restricted immune response in genetically susceptible individuals — a gene-environment interaction model that now underpins much of the understanding of ACPA-positive RA.

The role of the oral and lung mucosa

Two mucosal surfaces have emerged as likely sites where citrullination and early ACPA formation occurs. The lung, as described in the Klareskog smoking model, is one. Periodontal tissue is the other. Wegner and colleagues, writing in Arthritis and Rheumatism in 2010, showed that a PAD enzyme from the periodontal pathogen Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase — creating citrullinated substrates capable of driving anti-CCP formation. Konig and colleagues, in a 2016 paper in Science Translational Medicine, documented that Aggregatibacter actinomycetemcomitans induces hypercitrullination through a pore-forming toxin that dysregulates intracellular calcium — further implicating periodontal infection in early ACPA pathogenesis. These findings explain the epidemiological association between periodontitis and RA risk.

The Anti-CCP Test in the Context of Rheumatoid Arthritis

Sensitivity and specificity

The anti-CCP test is one of the most specific serological markers currently available for rheumatoid arthritis. A systematic review by Whiting and colleagues, published in Annals of Internal Medicine in 2010, pooled data from 151 diagnostic studies and reported sensitivity of approximately 67% and specificity of approximately 95%. This means the test correctly identifies approximately two-thirds of people with RA (sensitivity) while producing a true-positive result in approximately 19 of 20 positive tests in the RA context (specificity). Avouac and colleagues, in a systematic review published in Annals of the Rheumatic Diseases in 2006, calculated a positive likelihood ratio of approximately 12 for anti-CCP in RA diagnosis — meaning a positive test shifts the post-test probability of RA substantially upward from the pre-test probability, regardless of starting prevalence. The test's high specificity is what gives a positive result its clinical weight.

How anti-CCP fits the ACR/EULAR classification criteria

Anti-CCP occupies a formal role in the diagnostic framework for RA. The 2010 ACR/EULAR classification criteria assign points across four domains: joint involvement, serology, acute-phase reactants, and symptom duration. Serology is one of the highest-weighted domains, with a low-positive anti-CCP result (more than zero but not exceeding 3 times the upper limit of normal) contributing 2 points and a high-positive result (greater than 3 times the upper limit of normal) contributing 3 points toward the 6-point threshold required for RA classification. Radner and colleagues, in a 2014 systematic review of the classification criteria in Annals of the Rheumatic Diseases, documented the performance of these criteria across diverse populations. The explicit inclusion of anti-CCP in internationally validated classification criteria reflects both its diagnostic accuracy and its prognostic utility.

Why CCP matters for early and preclinical detection

Anti-CCP antibodies frequently precede the onset of clinical RA by several years. This preclinical phase is well-documented in prospective cohort studies. A study by Rantapää-Dahlqvist and colleagues, published in Arthritis and Rheumatism in 2003, identified anti-CCP in stored blood samples predating RA diagnosis by a median of several years using samples from a population-based biobank. Nielen and colleagues, in a 2004 case-control study embedded in a Dutch blood donor cohort, found that autoantibodies including anti-CCP were detectable a median of 4.5 years before RA onset. Deane, Norris, and Holers, in a 2010 review in Rheumatic Disease Clinics of North America, characterized the preclinical RA phase and the investigational potential for early intervention in anti-CCP-positive individuals before joint inflammation is established. Mankia and Emery, writing in Current Opinion in Rheumatology in 2016, framed anti-CCP-positive at-risk individuals as a target population for early-intervention research, noting that this window before clinical arthritis may represent a high-impact moment for rheumatological investigation.

How the Anti-CCP Test Works

What type of sample is used

Anti-CCP testing requires a standard venous blood draw, collected in a serum separator tube. The assay is performed on serum (the liquid fraction of blood after clotting and centrifugation), not plasma. The test does not require an EDTA anticoagulant tube. Nijenhuis and colleagues, in a 2004 review in Clinica Chimica Acta, described the laboratory methodology of anti-CCP assays in detail, noting that current commercial assays use an enzyme-linked immunosorbent assay (ELISA) format with cyclic citrullinated peptides as the capture antigen. Results are quantitative, expressed in U/mL, and are reproducible across certified clinical laboratories.

Fasting requirements

No fasting is required before an anti-CCP blood test. The antibody level is not affected by food intake, time of day, or recent physical activity. Standard venipuncture preparation applies: the draw site should be clean and accessible.

Timing and turnaround

Anti-CCP results are typically available within 1 to 3 business days from a CLIA-certified clinical laboratory. The test can be performed on the same sample as rheumatoid factor, inflammatory markers (ESR, CRP), and a complete blood count, making it efficient to include in a single rheumatological evaluation draw.

CCP2 versus CCP3 assay generations

Commercial anti-CCP assays have evolved through several generations. Second-generation assays (CCP2) introduced cyclic peptides as antigens, substantially improving specificity over first-generation linear-peptide assays. Third-generation assays (CCP3) use a modified antigen pool, offering incremental improvements in sensitivity — particularly in early disease — while maintaining the high specificity of CCP2. When comparing results across time or between providers, noting which assay generation was used is important, as numeric values are not directly interchangeable across platforms.

Factors That Affect Anti-CCP Results

Several biological and technical factors can influence anti-CCP levels and their interpretation. Understanding these confounders is essential for contextualizing a result that falls near the threshold.

• Disease stage — Affects detectability: Anti-CCP sensitivity is highest in established RA and lower in very early disease; a negative result in the first weeks of symptoms does not exclude future seroconversion.
• Smoking history — Raises anti-CCP likelihood: Smoking is associated with increased PAD activation in lung tissue and is a documented environmental trigger for anti-CCP positivity in HLA-susceptible individuals.
• Periodontal disease — Associated with higher levels: Periodontal pathogens express PAD-like enzymes; active periodontal disease is associated with higher anti-CCP titers and may confound interpretation in the context of otherwise mild joint symptoms.
• Tuberculosis and select infections — Can cause false positives: Anti-CCP positivity has been documented in TB patients; providers evaluating a positive anti-CCP in a patient with TB risk factors should consider this differential.
• Immunosuppressive therapy — May reduce titers: DMARDs and biologics used in RA management can reduce anti-CCP titers over time; serial measurements taken during active treatment may read lower than pre-treatment baseline values.
• Assay platform — Affects numeric values: CCP2 and CCP3 assays produce results on different scales; a value of 40 U/mL on one platform is not equivalent to 40 U/mL on another.

Companion Biomarkers Worth Testing Alongside Anti-CCP

Anti-CCP rarely tells the complete story in isolation. Testing it alongside CRP and rheumatoid factor provides a more complete picture of inflammatory activity and autoantibody pattern than any single marker alone.

• C-reactive protein (CRP): Measures systemic inflammatory activity. Why test alongside anti-CCP: Anti-CCP reflects autoantibody burden; CRP reflects active inflammation. The combination reveals whether the immune response is currently active in addition to being present.
• Rheumatoid factor (RF): A separate autoantibody with overlapping but distinct diagnostic utility. Why test alongside anti-CCP: Approximately 20–30% of RA patients are positive for RF but negative for anti-CCP, or vice versa; testing both captures a broader proportion of seropositive RA.
• Erythrocyte sedimentation rate (ESR): A non-specific marker of systemic inflammation. Why test alongside anti-CCP: Elevated ESR alongside a positive anti-CCP strengthens the case for active inflammatory arthritis and contributes to ACR/EULAR classification scoring.
• Antinuclear antibody (ANA): Screens for systemic autoimmune disease broadly. Why test alongside anti-CCP: Some autoimmune conditions that cause inflammatory arthritis, such as systemic lupus erythematosus, are ANA-positive but anti-CCP-negative; testing both helps differentiate RA from lupus-associated arthritis.

When to Take This Seriously

A positive anti-CCP result warrants rheumatological evaluation regardless of symptom severity. The test's high specificity means a positive result in a person with any joint symptoms — swelling, morning stiffness lasting more than 30 minutes, symmetric involvement of small joints — is a strong signal for further workup. In asymptomatic individuals who receive a positive anti-CCP incidentally, Berglin and colleagues, in a 2004 paper in Arthritis Research and Therapy, demonstrated that the combination of anti-CCP positivity with HLA-DRB1 shared epitope carriage is strongly associated with future RA development. Such individuals benefit from monitoring by a provider familiar with preclinical autoimmune disease. A strongly positive anti-CCP (greater than 3 times the upper limit of normal) in the setting of inflammatory joint symptoms is a clinical finding that generally prompts referral to rheumatology without delay. A weakly positive result in an otherwise asymptomatic individual is less definitive and warrants repeat testing and clinical correlation. A negative result does not rule out RA — the test's sensitivity of approximately 67% means roughly one-third of people with RA will not be captured by anti-CCP testing alone.

Reviewed by: [Named clinician, MD/DO, credentials] — [Publication date]